Skip to main content

Jonathan L. Kravetz

Member Emerita

Share:

Jon retired from Mintz and his roles as Chair of the Securities & Capital Markets Practice Group and Co-chair of the Life Sciences Practice Group in 2024.

viewpoints

ESG Thumbnail

Caremark Liability Following the SEC’s New ESG Reporting Requirements

December 16, 2022 | Blog | By Jacob Hupart, Doug Baumstein, Jonathan L. Kravetz, Ellen Shapiro, Will G. McKitterick

Read more
Read about how institutional investors, proxy advisors, society, and asset managers are using their voting power to influence companies to adopt Environmental, Social and Governance (ESG) governance factors and goals.
Read more

Environmental Disclosures: Considerations for Board Members

September 17, 2021 | Blog | By Jacob Hupart, Megan Gates, Jonathan L. Kravetz, Doug Baumstein

Read more

Life Sciences Newsletter — September 2021

September 1, 2021 | Article | By Adam Lenain, William Whelan, Jonathan L. Kravetz, Terri Shieh-Newton

This edition covers return-to-work challenges, insight on patenting AI innovations, FDA guidance on medical devices, transactional and IP activity in the life sciences, and recent Mintz work for life sciences clients.
Read more
Read less

News & Press

Press Release Thumbnail Mintz

187 Mintz attorneys have been recognized by Best Lawyers® in the 2025 edition of The Best Lawyers in America©. Notably, three Mintz attorneys received 2025 “Lawyer of the Year” awards, and 64 firm attorneys were included in the 2025 edition of Best Lawyers: Ones to Watch.

News Thumbnail Mintz

Members Douglas P. BaumsteinJacob H. Hupart, and Securities & Capital Markets Chair and Life Sciences Co-Chair Jonathan L. Kravetz, and Associates Will G. McKitterick and Ellen Shapiro authored an article for the New York Law Journal analyzing the role corporate boards play in monitoring and overseeing a company's operations, particularly in light of the SEC's imminent ESG disclosure rules.

Press Release Thumbnail Mintz
Mintz advised Cardurion Pharmaceuticals, Inc., a biotechnology company developing novel therapeutics to treat heart failure and other cardiovascular diseases, in a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity that will enable the Boston-based company to expand its drug discovery programs.
Press Release Thumbnail Mintz
In the latest guide, Mintz garnered rankings as a top national firm in eight practice areas, and 32 firm attorneys were individually recognized.
Press Release Thumbnail Mintz
Firm plays a key role in the largest health care acquisition to date in 2020.
Mintz represented G1 Therapeutics, Inc. in its initial public offering of 7,781,564 shares of common stock. G1 Therapeutics is a clinical-stage biopharmaceutical company.
Fifty-three Mintz attorneys have been named Massachusetts Super Lawyers for 2016 and thirty-one have been named Massachusetts Rising Stars. The findings will be published in the November 2016 issue of Boston Magazine and in a stand-alone magazine, New England Super Lawyers. 
Attorneys from Mintz represented Myriad Genetics, Inc. in its acquisition of Assurex Health, an informatics-based precision medicine company providing treatment decision support to health care providers for mental health patients.
Best Lawyers named 73 Mintz attorneys to its 2017 list of The Best Lawyers in America. Mintz attorneys selected for inclusion in this year’s list span 44 practice areas. 
Best Lawyers named 73 Mintz attorneys to its 2017 list of The Best Lawyers in America. Mintz attorneys selected for inclusion in this year’s list span 44 practice areas. 
Firm’s National Healthcare Practice, NY Corporate/M&A and Litigation: General Commercial Among Newest Rankings
The 2015 Chambers USA: America's Leading Lawyers for Business guide names 52 Mintz, Cohn, Ferris, Glovsky and Popeo, P.C.  attorneys as “Leaders in Their Fields.”
Read less

Jonathan L. Kravetz

Member Emerita